16 completed, 4 active not recruiting, 2 recruiting, 2 terminated. 8 Phase 3, 8 Phase 4, 5 Phase 2, 1 Early Phase 1, 1 Phase 1.
Follow tildrakizumab: new trials by email Literature Review of tildrakizumab trials Research Report on tildrakizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. Tildrakizumab 100 mg, Placebo - Moderate to Severe Genital Psoriasis | Phase 3 | Active not recruiting | Sun Pharmaceutical Industries Limited | 206 | 2025-03-21 | 2026-09-01 |
| A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting Tildrakizumab - Plaque Psoriasis | Active not recruiting | Almirall, S.A. | 42 | 2024-04-04 | 2025-06-24 | |
| A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO) Tildrakizumab - Genital Psoriasis | Recruiting | Almirall, S.A. | 110 | 2023-11-14 | 2025-01-29 | |
| A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis Tildrakizumab - Plaque Psoriasis | Recruiting | Almirall, S.A. | 50 | 2023-09-06 | 2025-01-29 | |
| Tilrdakizumab Almirall Tildrakizumab - Psoriasis | Active not recruiting | University Hospital Schleswig-Holstein | 3 | 2023-06-27 | 2025-11-24 | |
| Effects of Tildrakizumab on Epigenetic Age TILDRAKIZUMAB - Psoriasis, Aging | Phase 4 | Completed | Carlos Wambier | 30 | 2022-04-08 | 2024-07-18 |
| Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study Tildrakizumab - Plaque Psoriasis | Completed | Almirall, S.A. | 782 | 2021-11-22 | 2025-05-11 | |
| Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo Tildrakizumab - Skin and Connective Tissue Diseases, Skin Diseases | Early Phase 1 | Completed | Premier Specialists, Australia | 12 | 2021-09-16 | 2024-11-12 |
| Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis Tildrakizumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis | Phase 3 | Completed | Sun Pharmaceutical Industries Limited | 99 | 2021-05-13 | 2026-04-01 |
| A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis Tildrakizumab 100 mg, Placebo - Plaque Psoriasis | Phase 3 | Completed | Shenzhen Kangzhe Pharmaceutical Co., Ltd. | 220 | 2020-12-17 | 2023-04-12 |
| Abiraterone Acetate in Combination With Tildrakizumab Abiraterone Acetate, Tildrakizumab - Metastatic Castration Resistant Prostate Cancer | Phase 1 / Phase 2 | Terminated | Institute of Cancer Research, United Kingdom | 13 | 2020-12-01 | 2024-04-25 |
| Predicting Inflammatory Skin Disease Response to IL-23 Blockade Tildrakizumab - Psoriasis Vulgaris | Phase 4 | Completed | University of California, San Francisco | 7 | 2020-09-16 | 2024-04-30 |
| Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis Secukinumab, Ixekizumab, Brodalumab - Psoriasis, Psoriasis Vulgaris | Phase 4 | Completed | Radboud University Medical Center | 244 | 2020-08-20 | 2026-03-17 |
| MIcrovascular dysfuNction In Moderate-severe Psoriasis Tildrakizumab - Psoriasis, Cardiovascular Disease | Phase 4 | Completed | Marcelo F. Di Carli, MD, FACC | 36 | 2020-04-04 | 2025-11-25 |
| Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease Tildrakizumab - Hematologic Malignancies | Phase 2 | Completed | Medical College of Wisconsin | 51 | 2020-03-01 | 2025-10-21 |
| Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis Tildrakizumab - Plaque Psoriasis | Phase 4 | Terminated | Almirall, S.A. | 47 | 2020-01-29 | 2021-12-08 |
| A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis Tildrakizumab, Placebo, Etanercept - Moderate-to-severe Chronic Plaque Psoriasis | Phase 2 / Phase 3 | Active not recruiting | Sun Pharmaceutical Industries Limited | 135 | 2020-01-15 | 2026-04-15 |
| Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE) Tildrakizumab 100 mg Solution for Injection - Plaque Psoriasis | Phase 4 | Completed | Almirall, S.A. | 178 | 2019-12-17 | 2023-03-03 |
| Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice Tildrakizumab - Plaque Psoriasis | Completed | Almirall, S.A. | 331 | 2019-10-30 | 2026-03-02 |
Showing 20 of 26. Sign in to see all of them.
Psoriasis (9) · Skin Diseases (3) · Arthritis, Psoriatic (1) · Cardiovascular Diseases (1) · Dermatitis (1) · Dermatitis, Atopic (1) · Graft vs Host Disease (1) · Hematologic Neoplasms (1) · Hypopigmentation (1) · Pigmentation Disorders (1) · Skin Diseases, Papulosquamous (1) · Skin and Connective Tissue Diseases (1) · Vitiligo (1)
Almirall, S.A. (8) · Sun Pharmaceutical Industries Limited (7) · University of California, San Francisco (2) · Carlos Wambier (1) · Institute of Cancer Research, United Kingdom (1) · Marcelo F. Di Carli, MD, FACC (1) · Medical College of Wisconsin (1) · Merck Sharp & Dohme LLC (1) · Premier Specialists, Australia (1) · Radboud University Medical Center (1) · Shenzhen Kangzhe Pharmaceutical Co., Ltd. (1) · University Hospital Schleswig-Holstein (1)
United States (9) · Germany (4) · Poland (4) · Austria (3) · Hungary (3) · Spain (3) · Australia (2) · Belgium (2) · Italy (2) · Netherlands (2) · United Kingdom (2) · Argentina (1) · Bulgaria (1) · China (1) · Czechia (1)
Raymond Cho, MD, PhD (2) · Carlos G Wambier, MD, PhD (1) · Dedee Murrell, MD (1) · Elke de Jong, MD, PhD (1) · Johann De Bono, MD (1) · Marcelo F Di Carli, MD (1) · William Drobyski, MD (1)
PMID 30915660, PMID 32162721, PMID 28596043, PMID 31218661, PMID 31268369, PMID 36098877, PMID 40365708, PMID 41838287, PMID 26042589, PMID 33544883, PMID 33630387, PMID 34656148, PMID 36792337, PMID 38192233, PMID 40605963, PMID 41632629, PMID 42146323, PMID 42577288, PMID 42617697
2019 (3), 2009 (1)